Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients

• Published in: Biological & pharmaceutical bulletin Vol. 40; no. 9; pp. 1463 - 1467
• Main Authors: Mitsuboshi, Satoru, Yamada, Hitoshi, Nagai, Kazuhiko, Okajima, Hideo
• Format: Journal Article
• Language: English; Japanese
• Published: Japan The Pharmaceutical Society of Japan 2017; Pharmaceutical Society of Japan; Japan Science and Technology Agency
• Subjects: Adult; Aged; febuxostat; Febuxostat - adverse effects; Febuxostat - pharmacokinetics; Febuxostat - therapeutic use; Female; Follow-Up Studies; Hemodialysis; Humans; Hyperuricemia - drug therapy; Laboratories; Male; Middle Aged; Nitriles - adverse effects; Nitriles - pharmacokinetics; Nitriles - therapeutic use; Prospective Studies; Pyridines - adverse effects; Pyridines - pharmacokinetics; Pyridines - therapeutic use; Renal Dialysis; serum concentration; serum uric acid level; topiroxostat; Uric acid; Uric Acid - blood; Uricosuric Agents - adverse effects; Uricosuric Agents - pharmacokinetics; Uricosuric Agents - therapeutic use; topiroxostat; hemodialysis; serum concentration; febuxostat; serum uric acid level

To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum concentration of topiroxostat in HD patients after the switch. In this 16-month prospective observational study, we assessed the serum uric acid...